274 related articles for article (PubMed ID: 17118841)
1. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy.
Bal CS; Kumar A; Chandra P; Dwivedi SN; Pant GS
Acta Oncol; 2006; 45(8):1067-72. PubMed ID: 17118841
[TBL] [Abstract][Full Text] [Related]
2. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness of high-dosage radioiodine therapy in the elimination of remnant tissue following total thyroidectomy].
Schümichen C; Bulczak-Schmidt M; Blattmann H; Pauli-Harnasch C
Nuklearmedizin; 1984 Oct; 23(5):265-9. PubMed ID: 6522276
[TBL] [Abstract][Full Text] [Related]
4. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
Bal CS; Kumar A; Pant GS
Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the efficacy of iodine-131 for thyroid ablation.
Comtois R; Thériault C; Del Vecchio P
J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
[TBL] [Abstract][Full Text] [Related]
7. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
Doi SA; Woodhouse NJ
Clin Endocrinol (Oxf); 2000 Jun; 52(6):765-73. PubMed ID: 10848882
[TBL] [Abstract][Full Text] [Related]
8. Large remnant 131I ablation as an alternative to completion/total thyroidectomy in the treatment of well-differentiated thyroid cancer.
Leblanc G; Tabah R; Liberman M; Sampalis J; Younan R; How J
Surgery; 2004 Dec; 136(6):1275-80. PubMed ID: 15657587
[TBL] [Abstract][Full Text] [Related]
9. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
11. Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants.
Arad E; Flannery K; Wilson GA; O'Mara RE
Clin Nucl Med; 1990 Oct; 15(10):676-7. PubMed ID: 2225668
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer.
Johansen K; Woodhouse NJ; Odugbesan O
J Nucl Med; 1991 Feb; 32(2):252-4. PubMed ID: 1992028
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when.
Barbaro D; Boni G
Eur J Surg Oncol; 2007 Jun; 33(5):535-40. PubMed ID: 17337154
[TBL] [Abstract][Full Text] [Related]
14. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
Logue JP; Tsang RW; Brierley JD; Simpson WJ
Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
[TBL] [Abstract][Full Text] [Related]
15. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
[TBL] [Abstract][Full Text] [Related]
16. Differentiated thyroid cancer: lobectomy and radioiodine, a treatment suitable for all cases?
Allan E; Owens SE; Waller ML
Nucl Med Commun; 1999 Nov; 20(11):983-9. PubMed ID: 10572907
[TBL] [Abstract][Full Text] [Related]
17. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
18. [Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer].
Gawkowska-Suwińska M; Turska M; Roskosz J; Puch Z; Jurecka-Tuleja B; Handkiewicz-Junak D; Wygoda Z; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():278-88. PubMed ID: 12182036
[TBL] [Abstract][Full Text] [Related]
19. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
20. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
